US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical (Trajan) has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration (US FDA) as Class I for therapeutic and in vitro diagnostic (IVD) use.
This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.
This enables hemaPEN to be used to collect blood microsamples for clinical trials, diagnostics and applications to monitor health.
hemaPEN provides a convenient sampling procedure for collection and storage of four dried blood spot (DBS) samples. Unlike conventional DBS sampling tools, hemaPEN enables collection of an accurate and precise fixed micro-volume and is designed to maintain sample integrity for quantitative analysis. An easy-to-use sophisticated microsampling tool in the hands of non-analysts.
Remote microsampling facilitates more flexible blood sampling compared to traditional phlebotomy (blood draw) for scientific and clinical communities, for rapid R&D and implementation of new healthcare solutions for the public.
Trajan believes in science that benefits people – creating portable and affordable measurement solutions, enabling accurate results to inform preventative healthcare.
Visit www.hemapen.com to purchase or learn more about hemaPEN, and to sign up for updates.
To learn more about Trajan’s microsampling technologies and capabilities visit www.trajanscimed.com/microsampling.
Download
Press release [PDF]
Related news
The third leg in at-home healthcare – microsampling
CE mark for Trajan’s hemaPEN blood microsampling device, now available for diagnostic use across EU and UK
Trajan’s hemaPEN included on TGA’s ARTG as first blood microsampling device for use in Australia
Pens and prospering as a manufacturer
More information
www.hemapen.com
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 7703 828 309
media@trajanscimed.com
Interested in hemaPEN and microsampling innovations?
 has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration (US FDA) as Class I for therapeutic and in vitro diagnostic (IVD) use.
This follows the hemaPEN’s recen...&media=//cdn.shopify.com/s/files/1/0767/9441/articles/IM_3297_RevB_72dpi_1921x1181px_RGB_600x.jpg?v=1593594103){kind=link}
Also in News
Interview: Why data quality plays a critical role in personalized medicine, with microsampling expert Dr Michele Protti
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan celebrates International Pathology Day with ScyTek Laboratories to deliver quality IHC solutions
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.